Abstracts

LOW HIV-1 RESISTANCE IN SUBJECTS USING DARUNAVIR ONCE-DAILY REGIMENS ACROSS STUDIES

Across Phase 2/3 studies evaluating once-daily (QD) darunavir (DRV) regimens, treatment-naïve (TN) or treatment experienced (TE), including virologically suppressed, HIV-1–infected subjects were treated for 48-192 wk. We summarize treatment-emergent drug resistance-associated mutations (RAMs) for subjects receiving DRV QD dosing from 7 studies. Sponsored studies with available genotypes were assessed. TN studies: ARTEMIS (N=343; DRV+ritonavir [r]+emtricitabine…

CLINICAL VALIDATION OF A NOVEL DIAGNOSTIC HIV-2 TOTAL NUCLEIC ACID QUALITATIVE ASSAY

The current 4th-generation HIV diagnostic screening algorithm utilizes HIV-1/2 antigen/antibody combination immunoassays. Reactive samples are then tested by orthogonal immunoassays to confirm and discriminate between HIV-1 and HIV-2 antibodies. Additional HIV nucleic acid testing (NAT) is often required to resolve indeterminate or undifferentiated HIV seroreactivity. Undetectable HIV-2 plasma RNA (<10 copies/mL) is reported in one-third…

EVALUATION OF FDA-APPROVED RAPID HIV TESTS FOR LABORATORY DIAGNOSIS OF HIV INFECTION

The 2014 revised CDC/APHL Guidelines for Laboratory Diagnosis of HIV infection recommend that reactive antigen/antibody (ag/ab) screening tests be followed by a supplemental antibody test capable of differentiating HIV-1 from HIV-2. However, there is currently only one such supplemental test approved and available for use in the United States. We investigated the performance of other…

RECENCY STAGING OF HIV INFECTIONS THROUGH ROUTINE DIAGNOSTIC TESTING

Assay based staging of HIV for recency of infection has multiple purposes: at the population level, it enables cross-sectional incidence estimation. At the individual level, at diagnosis (as available in some national programmes and being contemplated in other large scale systems) recent/non-recent infection classification helps guide psychosocial support strategies, contact tracing, or inclusion in clinical…

DEVELOPMENT OF A HIGH-THROUGHPUT MULTIPLEX ASSAY FOR MEASURING HIV INCIDENCE

In order to assess the impact of HIV prevention strategies, it is critical to measure the rate at which new HIV infections are occurring in populations. To achieve needed performance requirements (e.g., long ‘mean duration of recent infection’ [MDRI], low ‘false recent rate’ [FRR]), most programs currently use multi-assay algorithms including avidity-modified antibody and viral…

IDENTIFYING RECENT HIV INFECTIONS: AN INDIVIDUALIZED ASSESSMENT OF RISK

The accurate identification of recent HIV infection remains an important area of research to inform population-based HIV prevention and treatment intervention policies. Methods that use cross-sectional testing and biomarker information might be an alternative to longitudinal testing, as combinations of serological and molecular methods can potentially provide a means to identify recent HIV infections. The…